KiraGen Bio

This is why we built @KiraGenBio. Base editing made CAR-T possible for patients like Alyssa, CURED of T-cell leukemia after every other option failed. We built the U.S. version at @BeamTx. Help us make more stories like Alyssa’s for patients with GBM and other solid tumors!

Big night for @KiraGenBio — won one of 5 @IgniteLC Golden Tickets on my 36th bday. $50K lab space + fellowship to advance our work in GBM and other solid tumors! Grateful to @LabCentral & sponsors @Bayer, @TakedaPharma, @EliLillyandCo, and @pfizer.

Our new website is live 🚀 KiraGen Bio is advancing multiplex-edited, off-the-shelf cell therapies designed to block tumor suppression signals and bring durable treatments to solid tumors. Explore more → kiragenbio.com

Meet the newest member of Team @KiraGenBio — our CAR-T cell mascot 🎧 Outfitted with AI-powered, noise-canceling headphones (our multiplex gene edits), it’s built to block out the solid tumor suppressive “noise” & keep fighting on! Designed to cure. Built to endure.

Our TME-Guards are like noise-cancelling headphones for CAR-T cells — silencing the suppressive signals of the tumor microenvironment so they can do their job.

We are honored to be part of the inaugural AI BioHub from @c10labs & @LabCentral—bringing AI and biology together to accelerate the future of drug development.

Our CEO @aedwards02 joined @jonchee_excedr on @Excedr’s Biotech Startups Podcast 🎙️ In Part 1 of 4, he shares how early wonder, queerness, & a few real-life “Ms. Frizzles” helped shape his path—and KiraGen’s mission to conquer the TME.

🚀 Big news! KiraGen Bio is a Boston Regional Finalist in the @HarvardHBS New Venture Competition – Alumni Track! This is a huge milestone for our AI-driven CAR-T therapies tackling solid tumors like GBM. Next stop: Global Finals for a chance at $75K! Onwards and Upwards! 🏆

What if you could address the fundamental barriers to cell therapy effectiveness in solid tumors, rather than merely mitigating secondary functional impairments?

What if you could target the root cause of cell therapy's limited success in solid tumors—the diverse immunosuppressive mechanisms within the tumor microenvironment (TME)?